针对革兰氏阴性菌的新治疗选择。 - Suppr

Suppr

超能文献

New treatment options against gram-negative organisms.

作者信息

Bassetti Matteo, Ginocchio Francesca, Mikulska Malgorzata

机构信息

Clinica Malattie Infettive, AOU San Martino, L,go R, Benzi 10, 16132 Genoa, Italy.

出版信息

Crit Care. 2011;15(2):215. doi: 10.1186/cc9997. Epub 2011 Mar 22.

DOI:10.1186/cc9997

PMID:21457501

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3219411/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb4b/3219411/fe35ad9387c1/cc9997-1.jpg

相似文献

New treatment options against gram-negative organisms.针对革兰氏阴性菌的新治疗选择。

Crit Care. 2011;15(2):215. doi: 10.1186/cc9997. Epub 2011 Mar 22.

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔：一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。

Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.

Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.1991年至2003年台湾某大学医院引起医院感染的革兰氏阴性菌中抗菌药物使用与抗菌药物耐药性之间的关系。

Int J Antimicrob Agents. 2005 Dec;26(6):463-72. doi: 10.1016/j.ijantimicag.2005.08.016. Epub 2005 Nov 8.

Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.耐革兰氏阴性菌引起的感染：流行病学与管理

Pharmacotherapy. 2015 Oct;35(10):949-62. doi: 10.1002/phar.1636.

Preserving the Dwindling β-lactams-Based Empiric Therapy Options for Gram-Negative Infections in Challenging Resistance Scenario: Lessons Learned and Way Forward.在耐药挑战的情况下保留日渐减少的基于β-内酰胺类的经验性治疗革兰氏阴性感染的治疗方案：经验教训和未来方向。

Microb Drug Resist. 2020 Jun;26(6):637-651. doi: 10.1089/mdr.2019.0195. Epub 2019 Dec 17.

Trends and correlation between antibacterial consumption and carbapenem resistance in gram-negative bacteria in a tertiary hospital in China from 2012 to 2019.2012 年至 2019 年中国一家三级医院革兰氏阴性菌中抗菌药物消耗与碳青霉烯类耐药性的趋势及相关性。

BMC Infect Dis. 2021 May 17;21(1):444. doi: 10.1186/s12879-021-06140-5.

Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.新型β-内酰胺-β-内酰胺酶抑制剂复方制剂：治疗碳青霉烯类耐药革兰氏阴性病原体的期望。

Expert Opin Drug Metab Toxicol. 2019 Feb;15(2):133-149. doi: 10.1080/17425255.2019.1563071. Epub 2019 Jan 10.

Antimicrobial Resistance in the Intensive Care Unit: A Focus on Gram-Negative Bacterial Infections.重症监护病房中的抗菌药物耐药性：聚焦革兰氏阴性菌感染

J Intensive Care Med. 2017 Jan;32(1):25-37. doi: 10.1177/0885066615619895. Epub 2016 Jan 15.

Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms.碳青霉烯类耐药革兰氏阴性菌的鉴定和治疗中的未解决问题。

Curr Opin Infect Dis. 2020 Dec;33(6):482-494. doi: 10.1097/QCO.0000000000000682.

Resistance in gram-negative bacteria: enterobacteriaceae.革兰氏阴性菌中的耐药性：肠杆菌科细菌

Am J Med. 2006 Jun;119(6 Suppl 1):S20-8; discussion S62-70. doi: 10.1016/j.amjmed.2006.03.013.

引用本文的文献

Hybrid Genome and Clinical Impact of Emerging Extensively Drug-Resistant Priority Bacterial Pathogen in Saudi Arabia.沙特阿拉伯新出现的广泛耐药重点细菌病原体的混合基因组及临床影响

Life (Basel). 2025 Jul 12;15(7):1094. doi: 10.3390/life15071094.

In vitro activity of cefiderocol against Gram-negative aerobic bacilli in planktonic and biofilm form-alone and in combination with bacteriophages.头孢地尔对浮游态和生物被膜态革兰氏阴性需氧杆菌的体外活性——单独及与噬菌体联合使用时的情况

Sci Rep. 2025 May 16;15(1):17105. doi: 10.1038/s41598-025-01704-w.

Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens.攻克外膜：促进化合物进入革兰氏阴性菌病原体。

NPJ Antimicrob Resist. 2023 Dec 20;1(1):17. doi: 10.1038/s44259-023-00016-1.

Antimicrobial Resistance and Extended-Spectrum Beta-Lactamase Genes in , and Isolates from the Uterus of Healthy Mares.健康母马子宫中大肠杆菌、肺炎克雷伯菌和奇异变形杆菌分离株的抗菌药物耐药性及超广谱β-内酰胺酶基因

Pathogens. 2023 Sep 8;12(9):1145. doi: 10.3390/pathogens12091145.

The Major Facilitator Superfamily and Antimicrobial Resistance Efflux Pumps of the ESKAPEE Pathogen .ESKAPEE 病原体的主要易化子超家族与抗菌耐药性外排泵

Antibiotics (Basel). 2023 Feb 7;12(2):343. doi: 10.3390/antibiotics12020343.

The Potential of Antibiotics and Nanomaterial Combinations as Therapeutic Strategies in the Management of Multidrug-Resistant Infections: A Review.抗生素与纳米材料联合应用于多重耐药感染治疗策略的潜力：综述。

Int J Mol Sci. 2022 Nov 30;23(23):15038. doi: 10.3390/ijms232315038.

Late-Stage Modification of Aminoglycoside Antibiotics Overcomes Bacterial Resistance Mediated by APH(3') Kinases.晚期修饰氨基糖苷类抗生素克服 APH(3') 激酶介导的细菌耐药性。

Chemistry. 2022 Jun 27;28(36):e202200883. doi: 10.1002/chem.202200883. Epub 2022 May 17.

Detrimental Effect of Ozone on Pathogenic Bacteria.臭氧对病原菌的有害影响。

Microorganisms. 2021 Dec 26;10(1):40. doi: 10.3390/microorganisms10010040.

Prevention, Diagnosis and Management of Post-Surgical Mediastinitis in Adults Consensus Guidelines of the Spanish Society of Cardiovascular Infections (), the Spanish Society of Thoracic and Cardiovascular Surgery () and the Biomedical Research Centre Network for Respiratory Diseases ().成人术后纵隔炎的预防、诊断与管理：西班牙心血管感染学会（）、西班牙胸心血管外科学会（）及呼吸疾病生物医学研究中心网络（）的共识指南

J Clin Med. 2021 Nov 26;10(23):5566. doi: 10.3390/jcm10235566.

The magnitude of extended-spectrum beta-lactamase- producing from clinical samples in Ethiopia: a systematic review and meta-analysis.埃塞俄比亚临床样本中产超广谱β-内酰胺酶的情况：一项系统评价和荟萃分析

Access Microbiol. 2021 Jan 28;3(3):000195. doi: 10.1099/acmi.0.000195. eCollection 2021 Mar.

本文引用的文献

Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study.印度、巴基斯坦和英国出现新的抗生素耐药机制：一项分子、生物学和流行病学研究。

Lancet Infect Dis. 2010 Sep;10(9):597-602. doi: 10.1016/S1473-3099(10)70143-2. Epub 2010 Aug 10.

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.CANVAS1 和 2 综合分析：3 期、多中心、随机、双盲研究，评估头孢洛林与万古霉素加氨曲南治疗复杂性皮肤和皮肤结构感染的安全性和疗效。

Clin Infect Dis. 2010 Sep 15;51(6):641-50. doi: 10.1086/655827.

New definitions of extended-spectrum β-lactamase conferring worldwide emerging antibiotic resistance.新的扩展谱β-内酰胺酶定义赋予了全球新兴的抗生素耐药性。

Med Res Rev. 2012 Jan;32(1):216-32. doi: 10.1002/med.20210. Epub 2010 Jun 23.

The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.“10x '20 倡议”：致力于在 2020 年前开发 10 种新型抗菌药物。

Clin Infect Dis. 2010 Apr 15;50(8):1081-3. doi: 10.1086/652237.

Beta-lactams and beta-lactamase-inhibitors in current- or potential-clinical practice: a comprehensive update.当前或潜在临床实践中的β-内酰胺类药物和β-内酰胺酶抑制剂：全面更新

Crit Rev Microbiol. 2009;35(2):81-108. doi: 10.1080/10408410902733979.

Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms.抗耐甲氧西林金黄色葡萄球菌碳青霉烯类药物雷祖培南（PTZ601）对具有明确耐药机制的肠杆菌科细菌的活性。

J Antimicrob Chemother. 2009 Aug;64(2):330-5. doi: 10.1093/jac/dkp187. Epub 2009 Jun 4.

ME1036, a novel carbapenem, with enhanced activity against clinical isolates causing bacteraemic community-acquired pneumonia.ME1036是一种新型碳青霉烯类药物，对引起菌血症的社区获得性肺炎临床分离株具有增强的活性。

J Antimicrob Chemother. 2009 Jul;64(1):209-10. doi: 10.1093/jac/dkp163. Epub 2009 May 9.

In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.头孢托罗单独及联合用药对耐药革兰氏阴性病原菌临床分离株的体外活性，包括产β-内酰胺酶的肠杆菌科细菌和铜绿假单胞菌。

Antimicrob Agents Chemother. 2009 Jun;53(6):2360-6. doi: 10.1128/AAC.01452-08. Epub 2009 Apr 6.

Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens.替加环素治疗多重耐药革兰阴性病原体感染

J Infect. 2009 Apr;58(4):273-84. doi: 10.1016/j.jinf.2009.02.009.

Current status of newer carbapenems.新型碳青霉烯类抗生素的现状

Curr Med Chem. 2009;16(5):564-75. doi: 10.2174/092986709787458498.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验